BTIG analyst Janine Stichter initiates coverage on Rocky Brands (NASDAQ:RCKY) with a Neutral rating.
Cancer Discovery Publishes Preclinical And Initial Clinical Data For MRTX1719 To Treat MTAP-Deleted Cancers through Novel Approach To MTA-Cooperative PRMT5 Inhibition
The detailed pharmacological and mechanistic characterization of MRTX1719 demonstrates that blocking PRMT5-MTA complex is a rational and differentiated approach to treat cancers harboring MTAP deletion
Partial responses
